BOLD Stock Analysis: Buy, Sell, or Hold?
BOLD - Boundless Bio, Inc. Common Stock
$2.87
0.17 (6.10%)
▲
5d:
+15.73%
30d:
+14.8%
90d:
+82.8%
HOLD
MODERATE Confidence
Analysis Updated: Aug 4, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Get Alerted When BOLD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: BOLD is 10.4% above its trading range ($2.60). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: BOLD is 10.4% above its trading range ($2.60). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: BOLD is currently trading at $2.87, which is considered extended relative to its 30-day fair value range of $2.42 to $2.60.
Technical Outlook: Technically, BOLD is in a strong uptrend. The price is approaching resistance at $2.75. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.1% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.00 (+47.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, BOLD is in a strong uptrend. The price is approaching resistance at $2.75. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.1% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.00 (+47.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.42 -
$2.60
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
45.8%
All Signals
- BEARISH: Price significantly overextended (+10.4% above its trading range)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.1%)
- BULLISH: Trading 47.9% below Wall St target ($4.00)
Trading Range Analysis
30-Day Trading Range
$2.42 -
$2.60
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$2.43
Resistance Level
$2.75
Current Trend
Strong Uptrend
Technical data as of
Aug 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.91
Wall Street Target
$4.00
(+47.9%)
Share & Embed Analysis
Last updated: August 05, 2026 10:25 AM ET
Data refreshes hourly during market hours. Next update: 11:25 AM
Data refreshes hourly during market hours. Next update: 11:25 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BOLD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$89 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 53 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
